LANCY(002612)2021-10-29 16:00Financial Performance - The company's revenue for Q3 2021 was ¥861,343,328.72, representing a 12.19% increase year-over-year[4] - Net profit attributable to shareholders for the same period was ¥64,699,107.95, up 22.37% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses reached ¥65,628,666.90, a significant increase of 44.19% year-over-year[4] - The company's operating revenue for the year-to-date period reached ¥2,650,707,735.25, representing a 32.75% increase compared to ¥1,996,695,846.24 in the same period last year[8] - The fashion women's wear segment achieved revenue of ¥1,214,930.9, a year-on-year growth of 41.40%[8] - The medical beauty business generated revenue of ¥821,017.5, reflecting a 37.37% increase year-on-year[8] - Net profit attributable to the parent company was ¥158,016,129.27, compared to ¥49,993,654.67 in the previous year, marking an increase of about 216.4%[23] - Operating profit for the quarter was ¥161,398,620.28, up from ¥50,772,569.54 in the same quarter last year, reflecting an increase of approximately 217.5%[23] - The total comprehensive income attributable to the parent company was ¥138,171,432.34, compared to ¥41,732,531.88 in the previous year, reflecting an increase of about 230.5%[25] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,279,327,893.08, reflecting a 21.84% increase from the end of the previous year[4] - The total assets and equity increased to ¥6,279,327,893.08 and ¥3,661,546,317.00 respectively, compared to ¥5,153,564,692.50 and ¥3,596,753,437.32 in the previous year, indicating a growth of 21.8% and 1.8%[20] - Current assets totaled RMB 2.09 billion, up from RMB 1.94 billion year-over-year, indicating a growth of about 7.5%[16] - Total liabilities reached RMB 2.62 billion, compared to RMB 1.56 billion at the end of 2020, marking an increase of around 67.9%[18] - The company's short-term borrowings rose significantly to RMB 492.18 million from RMB 135.18 million, indicating a substantial increase of approximately 264%[18] - Total liabilities amounted to ¥1,556,811,255.18, a decrease from ¥1,983,518,435.48[34] - Non-current liabilities totaled ¥528,682,483.93, down from ¥955,389,664.23[34] Cash Flow - The company reported a net cash flow from operating activities of ¥377,669,779.50, which is a 25.93% increase year-to-date[4] - The net cash flow from operating activities for Q3 2021 was CNY 377,669,779.50, an increase of 26% compared to CNY 299,898,492.86 in Q3 2020[28] - The total cash outflow from investing activities was CNY 1,888,274,393.57, up from CNY 1,165,318,430.47 in the same period last year, resulting in a net cash flow from investing activities of -CNY 530,323,484.76[28] - The cash inflow from financing activities reached CNY 899,288,800.00, significantly higher than CNY 117,460,556.74 in Q3 2020, leading to a net cash flow from financing activities of CNY 157,587,743.46[28] - The company reported a significant increase in cash paid for operating activities, totaling CNY 997,172,629.25, compared to CNY 668,097,767.98 in Q3 2020[28] - The cash received from investment activities was CNY 1,334,104,525.10, up from CNY 891,366,482.05 in the same quarter last year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,680[11] - The largest shareholder, Shen Dongri, holds 47.82% of the shares, amounting to 211,559,098 shares[11] Investments and Funds - The company established the "Bocheng No. 9 Fund" with a total scale of RMB 501 million, investing RMB 250 million as a limited partner to focus on equity investments in the medical beauty sector[13] - The "Lanzhi Wufang Medical Beauty Industry Fund" was set up with a total scale of RMB 501 million, with the company investing RMB 100 million as a limited partner[13] - The "Bocheng No. 10 Fund" is being established with a total scale of RMB 601 million, with the company planning to invest RMB 300 million as a limited partner[13] Research and Development - Research and development expenses increased to ¥76,091,484.03, up 35.99% from ¥55,954,962.55 in the previous year[8] - Research and development expenses increased to ¥76,091,484.03 from ¥55,954,962.55, showing a rise of about 36.1% year-over-year[21] Other Financial Metrics - The weighted average return on equity was 2.14%, an increase of 0.38% compared to the previous year[4] - The company's other comprehensive income showed a significant decline of 312.25%, with a loss of ¥26,200,177.17 due to increased foreign currency translation differences[8] - The income tax expense increased to ¥5,746,829.42, a 294.94% rise due to higher profits realized during the reporting period[8] - The implementation of the new leasing standards from January 1, 2021, did not have a significant impact on the company's financial status, operating results, or cash flows[34] - The third quarter report was not audited[35]